Published in AIDS Weekly, March 13th, 2006
The decrease in revenues was driven primarily by the timing of contract manufacturing shipments, partially offset by increased licensing revenues from Merck & Co., Inc. in 2005.
The company expects to recognize revenues of approximately $12.1 million in 2006 related to the manufacture of bulk DNA for the U.S. National Institutes of Health (NIH) in support of planned phase 2 HIV vaccine studies.
Financial results were consistent with the company's projected net loss for 2005 of between $23...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.